Skip to main content
Premium Trial:

Request an Annual Quote

Genomics Sector Limbers Up for Its Own M&A Boom; Diversity Matters

SAN FRANCISCO, Jan. 7 - Taking the lead from the broader biotech sector, US-based genomics tool and technology firms have entered into a state of increased consolidation, a leading industry analyst said.


Speaking privately with a reporter after a panel discussion about the current frenzy of biotech M&A activity, Douglas Braunstein, global head of mergers and acquisitions for JPMorgan H&Q, stressed that tool and tech companies with the best chance of tying the knot are those with a diverse portfolio.


"The tools and technology segment [of the genomics sector] is one in which you will see substantial amount of consolidation," said Braunstein. "The fundamentals of the [genomics] industry, from the tools standpoint, are one that having a diverse portfolio makes sense" because it help facilitate the customers they serve.


Nuptials that will not likely be celebrated, however, are the kinds between pharma or biotech firms with genomics tool or technology companies. While he didn't discount them wholesale, he said, "I don't think the logic is there." "Because, in part, you have the inherent conflict between your customers"—pharma and biotech companies—"and yourself," the tool maker.


The panel discussion at which Braunstein spoke, called "The Rationale for Mergers and Acquisitions in Biotechnology," was held during the 20th annual JPMorgan H&Q Healthcare Conference, held here through Thursday.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.